NEWGEN THERAPEUTICS INC has a total of 40 patent applications. It decreased the IP activity by 66.0%. Its first patent ever was published in 2010. It filed its patents most often in United States, Australia and Canada. Its main competitors in its focus markets pharmaceuticals and organic fine chemistry are PROTEZ PHARMACEUTICALS INC, EISENBRAND GERHARD and PHENOMIX CORP.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 8 | |
#2 | Australia | 4 | |
#3 | Canada | 4 | |
#4 | China | 4 | |
#5 | EPO (European Patent Office) | 4 | |
#6 | Singapore | 4 | |
#7 | Republic of Korea | 3 | |
#8 | WIPO (World Intellectual Property Organization) | 3 | |
#9 | Brazil | 2 | |
#10 | Israel | 2 | |
#11 | Mexico | 2 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Heterocyclic compounds | |
#3 | Medical preparations | |
#4 | Special acyclic compounds |
# | Name | Total Patents |
---|---|---|
#1 | Shen Wang | 37 |
#2 | Zhang Aimin | 37 |
#3 | Zheng Xiaoling | 37 |
#4 | Maung Jack | 30 |
#5 | Fan Junfa | 7 |
#6 | Xiao Wei | 4 |
#7 | Li Yingguang | 4 |
#8 | Wang Zhenzhong | 4 |
#9 | Guo Qingming | 4 |
#10 | Aimin Zhang | 1 |
Publication | Filing date | Title |
---|---|---|
EP2714703A1 | Tricyclic inhibitors of poly(adp-ribose)polymerase | |
CN103717590A | Quinazoline-7-ether compounds and methods of use | |
WO2012122058A2 | Alkyne substituted quinazoline compound and methods of use | |
EP2448409A1 | Phosphorus containing quinazoline compounds and methods of use |